PROPIVERINE HYDROCHLORIDE

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H29NO3.ClH
Molecular Weight	403.942
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCCOC(C(=O)OC1CCN(C)CC1)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=KFUJMHHNLGCTIJ-UHFFFAOYSA-N

InChI=1S/C23H29NO3.ClH/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21;/h4-13,21H,3,14-18H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	C23H29NO3
Molecular Weight	367.4813
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://media.mycme.com/documents/65/detrunorm-pi_16150.pdf
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/23288694

Propiverine is a well established antimuscarinic agent. It’s indicated in adults for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder syndrome or neurogenic detrusor overactivity (detrusor hyperreflexia) from spinal cord injuries, e.g. transverse legion paraplegia. As well as blocking muscarinic receptors in the detrusor muscle, the drug also inhibits cellular calcium influx, thereby diminishing muscle spasm. Overdose with the muscarinic receptor antagonist propiverine hydrochloride can potentially result in central anticholinergic effects, e.g. restlessness, dizziness, vertigo, disorders in speech and vision and muscular weakness. Moreover, severe dryness of mucosa, tachycardia and urinary retention may occur.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 162 Target ID: CHEMBL2094109 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26676219	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
Overactive bladder 39 Sources: http://media.mycme.com/documents/65/detrunorm-pi_16150.pdf	Primary		Approved 8583	Detrunorm Approved Use Tablets & capsules: Treatment of urinary incontinence, urgency and frequency in patients with idiopathic detrusor overactivity (overactive bladder). Tablets only: Neurogenic detrusor overactivity (detrusor hyperrefexia) from spinal cord injuries, e.g. transverse lesion paraplegia.
Urinary incontinence 14 Sources: http://media.mycme.com/documents/65/detrunorm-pi_16150.pdf	Primary		Approved 8583	Detrunorm Approved Use Tablets & capsules: Treatment of urinary incontinence, urgency and frequency in patients with idiopathic detrusor overactivity (overactive bladder). Tablets only: Neurogenic detrusor overactivity (detrusor hyperrefexia) from spinal cord injuries, e.g. transverse lesion paraplegia.

C_max

Value	Dose	Analyte	Population
155 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
221 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
645 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
819 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
97.58 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=28	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
102.18 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
48.5 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
62.9 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
136 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
56 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
196 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
393 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
562 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1100 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
508 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
281 ng/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
177 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
630 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PROPIVERINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
209 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
657 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=31 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PROPIVERINE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1345 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2512 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1139 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day multiple, oral dose: 15 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3200 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=32 \| https://pubmed.ncbi.nlm.nih.gov/9923582/	15 mg 3 times / day steady-state, oral dose: 15 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1886.4 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=28	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1799.67 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
483 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
615 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1348 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
558 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1403 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
3578 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4557 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
9519 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4058 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
5107 ng × h/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
25.87 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=28	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
28.21 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.4 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.8 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
14.1 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.9 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=29	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PROPIVERINE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.1 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
11.7 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
10.3 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.2 h OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=30	15 mg single, intravenous dose: 15 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PROPIVERINE N-OXIDE serum	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Analyte	Population
15.1% EXPERIMENT https://www.jstage.jst.go.jp/article/dmpk1986/6/1/6_1_3/_article/-char/en	PROPIVERINE serum	Homo sapiens
17.19% EXPERIMENT https://www.jstage.jst.go.jp/article/dmpk1986/6/1/6_1_3/_article/-char/en	PROPIVERINE N-OXIDE serum	Homo sapiens
40% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=33 \| https://pubmed.ncbi.nlm.nih.gov/9231343/	PROPIVERINE N-OXIDE serum	Homo sapiens
5% OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/470007_2590007F1323_1_V10_1F.pdf#page=33 \| https://pubmed.ncbi.nlm.nih.gov/9231343/	PROPIVERINE serum	Homo sapiens

Doses

Dose	Population	Adverse events
15 mg 3 times / day multiple, oral Recommended Dose: 15 mg, 3 times / day Route: oral Route: multiple Dose: 15 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10213329/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/10213329/	Sources: https://pubmed.ncbi.nlm.nih.gov/10213329/
20 mg 4 times / day multiple, oral Recommended Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/	Disc. AE: Flushing, Gastralgia... AEs leading to discontinuation/dose reduction: Flushing (2.3%) Gastralgia (2.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/

AEs

AE	Significance	Dose	Population
Flushing	2.3% Disc. AE	20 mg 4 times / day multiple, oral Recommended Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/
Gastralgia	2.3% Disc. AE	20 mg 4 times / day multiple, oral Recommended Dose: 20 mg, 4 times / day Route: oral Route: multiple Dose: 20 mg, 4 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/8578271/

PubMed

Title	Date	PubMed
Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: a prospective, randomized, single-blinded and multicenter clinical trial.	2011-04	21556215
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.	2000-05	10888308

Patents

Sample Use Guides

In Vivo Use Guide

Adults: Tablets: One 15 mg tablet twice a day, which may be increased to three times a day. Some patients may respond to one 15 mg tablet a day. For neurogenic detrusor overactivity: One 15 mg tablet three times a day; this may be increased to four times a day (maximum recommended daily dose). Capsules: One 30 mg capsule daily.

Route of Administration: Oral

In Vitro Use Guide

propiverine (3-10 uM) inhibited carbachol-induced contractions in the presence of verapamil and Ca(2+)-induced contractions in excess K+ medium containing atropine, suggesting it has both anticholinergic and Ca2+ channel blocking actions

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:16:49 GMT 2025` Edited by `admin` on `Mon Mar 31 18:16:49 GMT 2025`
Record UNII	DC4GZD10H3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROPIVERINE HYDROCHLORIDE

Common Name

English

DETRUNORM

Preferred Name

English

MICTONORM

Brand Name

English

P-4

Code

English

PROPIVERINE HYDROCHLORIDE [MI]

Common Name

English

Propiverine hydrochloride [WHO-DD]

Common Name

English

PROPIVERINE HYDROCHLORIDE [JAN]

Common Name

English

NSC-172140

Code

English

1-METHYL-4-PIPERIDYL DIPHENYLPROPOXYACETATE HYDROCHLORIDE

Systematic Name

English

MICTONETTEN

Brand Name

English

Code System Code Type Description

PUBCHEM

41125